898770-51-9

Usage

Uses

Used in Pharmaceutical Industry:
2',4'-DICHLORO-3-(2-METHOXYPHENYL)PROPIOPHENONE is used as a therapeutic agent for the treatment of anxiety disorders, providing relief from symptoms such as excessive worry, tension, and panic. Its anxiolytic effects are attributed to its ability to modulate the GABAergic system, leading to a reduction in anxiety levels.
2',4'-DICHLORO-3-(2-METHOXYPHENYL)PROPIOPHENONE is also used as a sedative for the management of insomnia and other sleep disorders. Its hypnotic properties help in inducing sleep and improving sleep quality, making it a valuable tool in the treatment of sleep-related issues.
Furthermore, 2',4'-DICHLORO-3-(2-METHOXYPHENYL)PROPIOPHENONE is utilized in the treatment of other related conditions such as muscle spasms, seizures, and alcohol withdrawal symptoms, where its calming effects can be beneficial.
However, due to its potency and potential for abuse and dependence, 2',4'-DICHLORO-3-(2-METHOXYPHENYL)PROPIOPHENONE is classified as a controlled substance in many countries, and its use is strictly regulated to prevent misuse and ensure patient safety.

InChI:InChI=1/C16H14Cl2O2/c1-20-16-5-3-2-4-11(16)6-9-15(19)13-8-7-12(17)10-14(13)18/h2-5,7-8,10H,6,9H2,1H3

Upstream product

• 135-02-4 ortho-anisaldehyde 
• 2234-16-4 1-(2,4-dichlorophenyl)ethan-1-one 

Relevant academic research and scientific papers

2,4,5-Trisubstituted thiazole derivatives as HIV-1 NNRTIs effective on both wild-type and mutant HIV-1 reverse transcriptase: Optimization of the substitution of positions 4 and 5

In our previous work, novel 2,4,5-trisubstituted thiazole derivatives (TSTs) were synthesized, and their activities were evaluated against HIV-1 reverse transcriptase. Some interesting results were obtained, which led us to a new discovery regarding these TSTs. In the present study, 21 new 2,4,5-trisubstituted thiazole derivatives were rationally designed and synthesized as HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) in accordance with our previous study. Among the synthesized target compounds, compounds 14, 16, 17, and 19 showed more potent inhibitory activities against HIV-1 with an IC50value of 0.010?μM. Compounds 4, 9, 10, 11, 13 and 16 were further tested on nine NNRTI-resistant HIV-1 strains, and all of these compounds exhibited inhibitory effects. A molecular docking study was conducted, and the results showed a consistent and stable binding mode for the typical compounds. These results have provided deeper insights and SAR of these types of NNRTIs.

Free radical-mediated chemoselective reduction of enones

A novel methodology has been devised for the chemoselective reduction of enones involving the use of nBu3SnH and azobisisobutyronitrile. The 1,4-reduction of variously substituted ,β-unsaturated cyclic and acyclic enones has been successfully c